- Recently completed NODE-301 and ongoing NODE-301B studies can be used as two efficacy studies supporting a future NDA submission (target p-values of
Milestone Pharmaceuticals Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT
Watch Milestone Pharmaceuticals' latest callMilestone Pharmaceuticals (NASDAQ:MIST) Q2 2026 Earnings Call · Replay · Aug 12Read the transcript of Milestone Pharmaceuticals (NASDAQ:MIST) Q2 2026 Earnings CallMilestone Pharmaceuticals Inc. on 6ix
Earlier from Milestone Pharmaceuticals
- Milestone Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Corporate Update
- Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment
- Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update
- Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update
- Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT
Later from Milestone Pharmaceuticals
- Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update
- Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
- Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants
- Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update
- Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
Follow Milestone Pharmaceuticals into a list and get an email when it puts out news.
Follow Milestone Pharmaceuticals